KR200348901Y1 - A Microcapsule of Nanoparticle Triclosan Using Supercritical Fluid - Google Patents
A Microcapsule of Nanoparticle Triclosan Using Supercritical Fluid Download PDFInfo
- Publication number
- KR200348901Y1 KR200348901Y1 KR20-2004-0002990U KR20040002990U KR200348901Y1 KR 200348901 Y1 KR200348901 Y1 KR 200348901Y1 KR 20040002990 U KR20040002990 U KR 20040002990U KR 200348901 Y1 KR200348901 Y1 KR 200348901Y1
- Authority
- KR
- South Korea
- Prior art keywords
- triclosan
- nanoparticle
- supercritical fluid
- present
- microcapsule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/128—Polymer particles coated by inorganic and non-macromolecular organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/005—Processes for mixing polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
본 고안은 환경친화적인 초임계 유체(Supercritical Fluid)를 이용한 나노입자 트리크로산의 미세입자 캡슐(Microcapsule)에 관한 것이다.The present invention relates to a microparticle capsule of nanoparticle trichromic acid using an environmentally friendly supercritical fluid.
본 고안에 따르면, 여드름, 염증, 아토피 등의 피부질환에 효과적인 나노입자의 트리크로산을 초임계 유체를 이용하여 미세입자 캡슐화로 하면 부작용을 최소화하고 일정한 시간동안 효능이 지속되는 약물을 개발할 수 있다.According to the present invention, by encapsulating nanoparticles triclosan effective for skin diseases such as acne, inflammation, and atopy by using microcritical fluid to encapsulate microparticles, it is possible to develop drugs that minimize side effects and maintain efficacy for a certain period of time. .
Description
본 고안은 환경친화적인 초임계 유체를 이용한 나노입자 트리크로산의 새로운 미세입자캡슐(Microencapsulation )에 관한 것이다.The present invention relates to a novel microencapsulation of nanoparticle trichromic acid using an environmentally friendly supercritical fluid.
일반적으로 여드름, 아토피성 피부염, 염증 등의 피부질환은 세계 전 인구의 10 내지 20%가 고통받는 것으로 추정되고 있고, 환경오염, 스트레스 등의 원인물질 증가로 최근 수십년 동안 발병율이 계속 상승되고 있고, 우리나라도 그 환자수가 늘고 있는 현실이다.In general, skin diseases such as acne, atopic dermatitis, and inflammation are estimated to suffer from 10 to 20% of the world's population. In Korea, the number of patients is increasing.
이러한 피부질환에 트리크로산이 여드름, 염증, 아토피 치료제로 많이 이용되고 있지만, 트리크로산이 입자형태로 의약품이나 화장품에 그대로 이용되기 때문에 피부 부작용등이 수반되는 일이 자주 발생하여, 화장품이나 의약외품 등에서 그 함량을 규제하고 있다.Although triclosan is widely used as a treatment for acne, inflammation, and atopic dermatitis, such skin diseases are often used in medicines and cosmetics in the form of particles. The content is regulated.
그리고 기존의 미세화캡슐공정은 인체에 해로운 용매와 고분자를 사용하기 때문에 약효지속성은 향상되지만 인체에 부작용이 수반된다.In addition, the existing micronized capsule process uses solvents and polymers that are harmful to the human body, so that the drug efficacy is improved, but the human body is accompanied with side effects.
본 고안은 상기한 바와 같은 종래 기술의 문제점을 해결하기 위한 것으로서, 나노입자 크기의 트리크로산 입자를 환경친화적인 초임계 유체와 생분해성 고분자를 이용한 미세입자 캡슐로 부작용을 최소화하고 약효지속성을 향상시킬 수 있다.The present invention is to solve the problems of the prior art as described above, to minimize the side effects and improve the drug sustainability of the microparticle capsules using environmentally friendly supercritical fluid and biodegradable polymer nanoparticle sized triclosan particles You can.
상기 목적을 달성하기 위한 본 고안에 따르면, 초임계 미세입자 캡슐은 초임계 이산화탄소와 생분해성 고분자인 폴리락타이드(Poly(L-lactides))용액, 약물인 트리크로산으로 구성된다.According to the present invention for achieving the above object, the supercritical microparticle capsule is composed of a supercritical carbon dioxide and a polylactide (Poly (L-lactides)) solution of the biodegradable polymer, the drug triclosan.
도 1은 초임계 유체를 이용한 나노입자 트리클로산의 미세입자 캡슐화 제조공정을 나타내고 있다.1 shows a process for producing microparticle encapsulation of nanoparticle triclosan using a supercritical fluid.
이하 본 고안을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
상기한 바와 같은 목적을 달성하기 위하여, 본 고안에서 사용되는 초임계 이산화탄소는 비휘발성, 무독성, 그리고 저렴한 가격뿐만 아니라 낮은 임계 온도를 가지고 있기 때문에 환경친화 용매이다. 또한 낮은 점도와 높은 확산성으로 핵생성속도가 빨라져 입자크기를 작게 하는 원동력이 되어 미세입자의 캡슐화를 이루도록 한다. 또한 본 고안에 사용되는 폴리락타이드는 생분해성 고분자로 피부에 친화적 이어서 피부 부작용을 최소화할 수 있고, 디메칠에테르와 혼합하여 5% 폴리락타이드용액을 제조한다. 본 고안에 사용되는 트리크로산은 피부질환 치료제이다.In order to achieve the object as described above, the supercritical carbon dioxide used in the present invention is an environmentally friendly solvent because it has a low critical temperature as well as non-volatile, non-toxic, and low price. In addition, the low viscosity and high diffusivity increases the nucleation speed, which makes the encapsulation of the fine particles to be the driving force to reduce the particle size. In addition, the polylactide used in the present invention is a biodegradable polymer that is friendly to the skin, thereby minimizing the side effects of the skin, and mixed with dimethyl ether to prepare a 5% polylactide solution. Triclosan used in the present invention is a therapeutic agent for skin diseases.
초임계를 이용한 미세입자 캡슐화공정이 도 1에 나타나 있으며, 공정을 다음과 같다. 초임계 이산화탄소와 나노입자의 트리크로산으로 충진된 반응기 내부에폴리락타이드 고분자용액을 펌프로 주입하면, 용매의 용해력을 급격하게 저하되면서 나노입자의 트리크로산 입자주위에 재결정되어 미세입자의 캡슐을 제조한다. 그 이후에 계속 초임계 이산화탄소를 주입하여 디메칠에테르를 완전히 제거하여 본 공정을 완성한다.Microparticle encapsulation process using a supercritical is shown in Figure 1, the process is as follows. When the polylactide polymer solution is injected into the reactor filled with supercritical carbon dioxide and trichromic acid of nanoparticles with a pump, the solvent dissolves rapidly and is recrystallized around the trichromic acid particles of the nanoparticles to encapsulate the microparticles. To prepare. After that, supercritical carbon dioxide is continuously injected to completely remove the dimethyl ether to complete the process.
본 공정에서 최적의 운전조건은 반응기의 압력이 80-300bar, 온도는 30-80도, 교반속도는 300-900rpm, 그리고 초임계 이산화탄소의 주입속도는 1.0-5.0ml/min, 고분자용액의 주입속도는 1.0-5.0ml/min이다. 위의 공정과 작업조건에서 0.1-10㎛ 크기의 미세입자의 캡슐을 얻을 수 있다.The optimum operating conditions in this process are 80-300 bar reactor temperature, 30-80 degrees temperature, 300-900 rpm stirring speed, and 1.0-5.0 ml / min injection rate of supercritical carbon dioxide. Is 1.0-5.0 ml / min. Under the above process and working conditions, a capsule of 0.1-10 μm in size can be obtained.
이상에서 설명한 바와 같이, 트리크로산을 그대로 함유된 제재에 비하여 본 고안에 의해 제조된 나노입자의 트리크로산의 미세화캡슐은 피부와 한꺼번에 과량이 접촉하지 않기 때문에 피부 부작용이 수반되지 않으며, 약효지속성도 오래 지속될 수 있다.As described above, the microcapsules of triclosan of the nanoparticles prepared by the present invention are not accompanied by excessive skin contact with the skin at the same time as compared to the preparation containing the tricroic acid as it is, and does not involve skin side effects, Can also last long.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20-2004-0002990U KR200348901Y1 (en) | 2004-02-06 | 2004-02-06 | A Microcapsule of Nanoparticle Triclosan Using Supercritical Fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20-2004-0002990U KR200348901Y1 (en) | 2004-02-06 | 2004-02-06 | A Microcapsule of Nanoparticle Triclosan Using Supercritical Fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR200348901Y1 true KR200348901Y1 (en) | 2004-04-29 |
Family
ID=49429158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20-2004-0002990U KR200348901Y1 (en) | 2004-02-06 | 2004-02-06 | A Microcapsule of Nanoparticle Triclosan Using Supercritical Fluid |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR200348901Y1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100867082B1 (en) * | 2008-06-05 | 2008-11-04 | 재단법인서울대학교산학협력재단 | Producting method of supercritical nanostructrue for skin remedy of acne and atopic dermatitits |
-
2004
- 2004-02-06 KR KR20-2004-0002990U patent/KR200348901Y1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100867082B1 (en) * | 2008-06-05 | 2008-11-04 | 재단법인서울대학교산학협력재단 | Producting method of supercritical nanostructrue for skin remedy of acne and atopic dermatitits |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pradhan | Microsponges as the versatile tool for drug delivery system | |
| Mandava et al. | Novel approach: microsponge drug delivery system | |
| Osmani et al. | A new cornucopia in topical drug delivery: microsponge technology | |
| KR20230061380A (en) | How to Preserve Reactive Active Compounds, Capsules and Formulations | |
| Tile et al. | Microsponges: a novel strategy for drug delivery | |
| CN108295045B (en) | Liquid crystal gel microcapsule and preparation method thereof | |
| EP2334286A1 (en) | Low ph retinoid topical compositions | |
| Wu et al. | Pickering emulsions-chitosan hydrogel beads carrier system for loading of resveratrol: Formulation approach and characterization studies | |
| Shafi et al. | Microsponge drug delivery system | |
| CN107714674A (en) | A kind of preparation method of PLGA microballoons | |
| AU2019320082A1 (en) | Particles containing coloring agents and methods of using the same | |
| Borawake et al. | Microsponge as an emerging technique in novel drug delivery system | |
| Phadke et al. | A recent update on drug delivery systems for pain management | |
| Palazzo et al. | Antioxidants entrapment in polycaprolactone microparticles using supercritical assisted injection in a liquid antisolvent | |
| KR200348901Y1 (en) | A Microcapsule of Nanoparticle Triclosan Using Supercritical Fluid | |
| JP2010180145A (en) | Method for producing tranexamic acid-containing nanoparticle and composite particle | |
| JP4637993B2 (en) | Microcapsule and manufacturing method thereof | |
| Russo et al. | Application of experimental design for the development of soft-capsules through a prilling, inverse gelation process | |
| US20180235924A1 (en) | Compositions for topical application comprising benzoyl peroxide and adapalene | |
| JP2015034153A (en) | Kit for external preparations for skin | |
| CN110585117A (en) | Thermo-sensitive gel preparation of phloretin and preparation method and application thereof | |
| JP2015110634A (en) | Kit for skin external preparation | |
| Huang et al. | Preparation and characterization of astaxanthin-loaded microcapsules stabilized by lecithin-chitosan-alginate interfaces with layer-by-layer assembly method | |
| CN100528956C (en) | Nano particle of enwrapping water-soluble active ingredient, and preparation method | |
| AU2014313817B2 (en) | Ionic gelation on solids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REGI | Registration of establishment | ||
| LAPS | Lapse due to unpaid annual fee |